

not limited to: antigens (such as proteins (including peptides)) and antibodies (including fragments thereof (FABs, etc.)); proteins and small molecules, including biotin/streptavidin; enzymes and substrates or inhibitors; other protein-protein interacting pairs; receptor-ligands; and carbohydrates and their binding partners. Nucleic acid - nucleic acid binding proteins pairs are also useful. In general, the smaller of the pair is attached to the NTP for incorporation into the primer. Preferred binding partner pairs include, but are not limited to, biotin and streptavidin, digoxin and Abs, and Prolinx™ reagents (see prolinxinc.com/ie4/home.html). ---

IN THE CLAIMS:

Please enter the following amended claim set:

9. A method of detecting a target sequence in a sample comprising:
 - (a) providing a substrate comprising an array of capture probes coated with a recombinase;
 - (b) contacting said target sequence with said array, to form an assay complex; and
 - (c) detecting said assay complex to detect said target sequence in said sample.
10. A method according to claim 9 wherein said recombinase is a recA recombinase.
11. A method according to claim 10 wherein said recA recombinase is *E. coli* recA.
12. A method according to claim 9 wherein said capture probes comprise said recombinase.
13. A method according to claim 9 wherein said target sequence comprises said recombinase.
14. A method according to claim 13 further comprising coating said target sequence with said recombinase.
15. A method according to claim 9 wherein said target sequence is RNA.
16. A method according to claim 15 wherein said RNA is coated with a recombinase.

REMARKS

Claims 9-16 are pending in the instant application. Claims 9-16 stand rejected under 35 U.S.C. § 112, first paragraph. Claims 9, 10, and 12-14 stand rejected under 35 U.S.C. 102(e) as being anticipated by Drmanac *et al.*, (U.S. Patent No. 6,383,742). Claims 9-16 stand rejected under 35 U.S.C. § 103(a) as unpatentable over Kiagawa *et al.*, (WO 98/08975) in view of Drmanac *et al.*, (U.S. Patent No. 6,383,742). Claims 11, 15 and 16 stand rejected under 35 U.S.C. §103(a) as unpatentable over Drmanac *et al.*, (U.S. Patent No. 6,383,742) in view of